Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marco Bellone
Observed names:
Bellone M,
M Bellone,
M. Bellone
Institution:
University of Genoa
Observed institution:
University of Genoa
ORCID:
0000-0002-6976-5509
Observed ORCID:
0000-0002-6976-5509
OpenAlex ID:
A5078323231
Propofol vs. inhalational agents to maintain general anaesthesia in ambulatory and in-patient surgery: a systematic review and meta-analysis
2018
·
Stefan Schraag
, Lorenzo Pradelli
, et al.
·
BMC Anesthesiology
·
231
PDF
ISPM: A DSS for personnel career management
1995
·
M. Bellone
, M. Merlino
, et al.
·
Decision Support Systems
·
10
Pharmacoeconomics of parenteral nutrition in surgical and critically ill patients receiving structured triglycerides in China.
2017
·
Guo Hao Wu
, Alexandra Ehm
, et al.
·
PubMed
·
6
Budget impact analysis of apixaban to treat and prevent venous thromboembolism in Italy
2016
·
Marco Bellone
, Roberto Di Virgilio
, et al.
·
Farmeconomia Health economics and therapeutic pathways
·
5
PDF
Budget Impact Analysis Of Apixaban Versus Other Noacs For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients
2014
·
L. Pradelli
, M. Calandriello
, et al.
·
Value in Health
·
4
PDF
A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy
2024
·
Marco Bellone
, Alice Sabinot
, et al.
·
Global & Regional Health Technology Assessment
·
3
PDF
Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy
2022
·
Patrizia Berto
, Marco Bellone
, et al.
·
Farmeconomia Health economics and therapeutic pathways
·
3
PDF
Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis
2021
·
Marco Bellone
, Lorenzo Pradelli
, et al.
·
ClinicoEconomics and Outcomes Research
·
3
PDF
Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer
2019
·
Ravasio R
, Tiseo M
, et al.
·
Global & Regional Health Technology Assessment
·
3
Comparative pharmacoeconomic assessment of apixaban vs. standard of care for the prevention of stroke in Italian atrial fibrillation patients
2014
·
Lorenzo Pradelli
, Mario Calandriello
, et al.
·
Farmeconomia Health economics and therapeutic pathways
·
3
PDF
Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients with Advanced Follicular Lymphoma: A Cost Analysis
2022
·
Marco Bellone
, Lorenzo Pradelli
, et al.
·
Farmeconomia Health economics and therapeutic pathways
·
2
PDF
Cost Effectiveness Analysis Of Apixaban Versus Other Noacs For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients
2014
·
L. Pradelli
, M. Calandriello
, et al.
·
Value in Health
·
2
Pharmacoeconomic Assessment Of Apixaban Versus Standard Of Care For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients
2014
·
L. Pradelli
, M. Calandriello
, et al.
·
Value in Health
·
2
PDF
A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy
2025
·
Stefano Luminari
, Antonio Pinto
, et al.
·
ClinicoEconomics and Outcomes Research
·
1
[Budget Impact Analysis of the Adjuvanted Quadrivalent Influenza Vaccine in the Elderly in Italy]
2022
·
Vincenzo Baldo
, Marco Bellone
·
Farmeconomia Health economics and therapeutic pathways
·
1
PDF
POSB108 Cost-Effectiveness and Cost-Utility Analyses of Atezolizumab-Based Therapy in Patients with Advanced or Unresectable Hepatocellular Carcinoma in Italy
2022
·
L Pradelli
, M Bellone
, et al.
·
Value in Health
·
1
Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation
2018
·
Marco Bellone
, Lorenzo Pradelli
, et al.
·
Farmeconomia Health economics and therapeutic pathways
·
1
PDF
Pharmaceutical Market Access Hurdles in Developed Countries
2018
·
G. Kockaya
, Albert I. Wertheimer
, et al.
·
1
Market Access in Italy
2018
·
Lorenzo Pradelli
, Marco Bellone
·
1
Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
2014
·
Lorenzo Pradelli
, Mario Calandriello
, et al.
·
Farmeconomia Health economics and therapeutic pathways
·
1
PDF
The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban
2014
·
Lorenzo Pradelli
, Mario Calandriello
, et al.
·
Farmeconomia Health economics and therapeutic pathways
·
1
PDF
Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy
2026
·
Donatella Panatto
, Marco Bellone
, et al.
·
ClinicoEconomics and Outcomes Research
PDF
EE253 Cost-Effectiveness of High-Dose Trivalent Influenza Vaccine in the Elderly: A Cohort-Based Economic Model From the Italian NHS Perspective
2025
·
Marco Bellone
, Alberto Piccolo
, et al.
·
Value in Health
CO146 Systematic Literature Review of Hospital Time and Resource Consumption in Subcutaneous and Intravenous Oncologic Biologic Therapies: The Case Study of Atezolizumab From an Italian Perspective
2024
·
M Bellone
, M Povero
, et al.
·
Value in Health
EE223 Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients With Advanced Follicular Lymphoma: A Cost Analysis
2022
·
M Bellone
, L Pradelli
, et al.
·
Value in Health
PDF
Show more works
View as search
Works count:
37
Citation count:
285
H-index:
4
I10-index:
2
Year
Topic
Type